Physician profile
Taylor Stone
NPI 1790175602
$5,189.82
in general payments reported to CMS, 2019-2025
24 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $833 · 2022: $835 · 2023: $1,134 · 2024: $993 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899 · Travel and Lodging: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.68 |
| Travel and Lodging | $623.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $927.14 | 2021-2025 | Repatha, Repatha |
| Intuitive Surgical, INC. | $623.52 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $531.68 | 2021-2025 | Farxiga, Brilinta, Lokelma |
| Novartis Pharmaceuticals Corporation | $507.75 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $423.86 | 2021-2023 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.11 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $289.02 | 2022-2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $249.99 | 2021-2024 | Xarelto |
| Pfizer INC. | $236.93 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $144.79 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $135.19 | 2021-2025 | Verquvo |
| Endologix LLC | $122.03 | 2024 | Endocross Device, Torus Stent Graft System |
| Sanofi-Aventis U.S. LLC | $111.98 | 2021-2024 | |
| Novo Nordisk INC | $109.80 | 2023-2025 | Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $88.02 | 2023 | Opsumit, Uptravi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.39 | 2024-2025 | Lifevest |
| Biotronik INC. | $64.91 | 2025 | Amvia Edge, Acticor 7 Vr-T Dx, Biomonitor |
| Emd Serono, INC. | $60.92 | 2022 | |
| Scpharmaceuticals INC. | $33.61 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $33.21 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.22 | 2025 | |
| Daiichi Sankyo INC. | $26.82 | 2024 | Injectafer |
| Cvrx, INC. | $18.21 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $14.72 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.